Core Viewpoint - The stock of Stone Pharmaceutical Group (01093) has fallen over 10%, currently trading at 9.72 HKD with a transaction volume of 2.563 billion HKD following the announcement of a strategic collaboration and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] Group 1: Strategic Collaboration - Stone Pharmaceutical Group has signed a strategic collaboration and licensing agreement with AstraZeneca covering a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects [1] - The agreement also includes plans for collaboration on an additional four new projects [1] Group 2: Financial Terms - The collaboration sets a new record for overseas business development transactions in the GLP-1 sector, with Stone Pharmaceutical Group receiving a prepayment of 1.2 billion USD [1] - The company is entitled to receive up to 3.5 billion USD in potential research milestone payments and up to 13.8 billion USD in potential sales milestone payments [1] - Additionally, Stone Pharmaceutical Group will earn a sales commission based on the annual net sales of related products, with potential total transaction value reaching up to 18.5 billion USD [1]
石药集团倒跌逾10% 与阿斯利康签订多肽药大单 潜在交易总额最高达185亿美元